Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Daniel Bryce Landi
Assistant Professor of Pediatrics
Pediatrics, Hematology-Oncology
daniel.landi@duke.edu
Box 102382, Durham, NC 27710
330 Trent Drive, Room 390, Durham, NC 27710
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Training & Certifications
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: false}
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
CONNECT1905: Phase 2 Study of Systemic IL-6 Receptor Antagonist ACTEMRA® (tocilizumab) for the treatment of Progressive/Recurrent Pediatric Adamantinomatous Craniopharyngioma
Clinical Trial
Principal Investigator ·
Awarded by Research Institute at Nationwide Children's Hospital ·
2024 - 2029
Phase 2 trial of a novel peptide vaccine targeting CMV antigen for newly diagnosed pediatric high grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
Research
Principal Investigator ·
Awarded by Food and Drug Administration ·
2021 - 2027
LOGGIC/FIREFLY-2: A Phase 3, Randomized, International Multicenter Trial of DAY101 Monotherapy Versus Standard of Care Chemotherapy in Patients with Pediatric Low-Grade Glioma Harboring an Activating RAF Alteration Requiring First-Line Systemic Thera
Clinical Trial
Principal Investigator ·
Awarded by Day One Biopharmaceuticals ·
2023 - 2027
A Phase 1/2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of Avapritinib in Pediatric Patients with Relapsed/Refractory Solid Tumors Harboring a Mutation in KIT or PDGFRA
Clinical Trial
Principal Investigator ·
Awarded by Blueprint Medicines Corporation ·
2022 - 2027
DAY 101-001, A Phase 2 Study of the Oral pan-RAF Inhibitor DAY101 in Pediatric Patients with BRAF-Mutated Low Grade Glioma
Clinical Trial
Principal Investigator ·
Awarded by DOT Therapeutics-1 ·
2021 - 2026
PNOC 029, "Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
Clinical Trial
Principal Investigator ·
Awarded by The Regents of the University of California ·
2023 - 2025
Connect 1906 Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma and diffuse intrinsic pontine glioma and recurrent medulloblastoma
Clinical Trial
Co-Principal Investigator ·
Awarded by Research Institute at Nationwide Children's Hospital ·
2024 - 2025
PNOC 017: A Target Validation /Phase1 Study of BGB-290 in Combination with Temozolomide in Adolescent and Young Adult IDH1/2 Newly Diagnosed and Recurrent Mutant Gliomas
Clinical Trial
Principal Investigator ·
Awarded by The Regents of the University of California ·
2023 - 2025
PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial D
Clinical Trial
Principal Investigator ·
Awarded by The Regents of the University of California ·
2023 - 2025
PNOC 019: A Randomized, Double-Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Combination Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Glioma (HGG)
Clinical Trial
Co-Principal Investigator ·
Awarded by The Regents of the University of California ·
2021 - 2024
Phase 2 PVSRIPO and the Checkpoint Inhibitor Pembrolizumab in Recurrent Glioblastoma
Clinical Trial
Principal Investigator ·
Awarded by Istari Oncology ·
2021 - 2024
A Randomized, Multicenter, Phase 2 Study of Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) Alone or in Combination with Lomustine in Recurrent WHO Grade IV Malignant Glioma Patients
Clinical Trial
Principal Investigator ·
Awarded by Istari Oncology ·
2018 - 2024
PNOC022 A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial D
Clinical Trial
Co-Principal Investigator ·
Awarded by The Regents of the University of California ·
2022 - 2023
Dose-finding and Safety Study of PVSRIPO Against Recurrent WHO Grade IV Malignant Glioma
Clinical Trial
Principal Investigator ·
Awarded by Istari Oncology ·
2020 - 2022
Qualitative Interviews with Recurrent Glioblastoma Patients and their Caregivers
Research
Principal Investigator ·
Awarded by Istari Oncology ·
2021 - 2022
PBTC-029
Research
Principal Investigator ·
Awarded by St. Jude Children's Research Hospital ·
2017 - 2022
